Skip to content

BioCryst Pharmaceuticals BCRX Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options

Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$57.3M+2,457%
Zymeworks logo
ZymeworksZYME
$8.72M+1,029%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
BioCryst Pharmaceuticals (BCRX) reported proceeds from issuance of shares under incentive and share based compensation plans including stock options of $19.48M in Q1 2026.
How has BioCryst Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options changed year-over-year?
BioCryst Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options increased by 715.0% year-over-year, from $2.39M to $19.48M.
What is the long-term trend for BioCryst Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options has grown at a -16.6% compound annual growth rate (CAGR), from $15.73M to $9.12M.
What does proceeds from issuance of shares under incentive and share based compensation plans including stock options mean?
Cash received from employees or directors upon the exercise of stock options or the purchase of shares through employee stock purchase plans. It serves as a measure of the cash inflow generated from equity-based compensation programs.